postmenopausal women Their fracture risk can be significantly reduced with a simple and cost-effective treatment: occasional IV infusions of zoledronate (Reclast). Research published in the New England Journal of Medicine shows long-term benefits of this bone-strengthening drug in reducing early-stage fractures in women. menopause,

key findings

A study led by Dr. Mark Boland, associate professor of medicine at the University of Auckland, New Zealand, showed that women aged 50 to 60 who received two injections of zoledronate over five years experienced the following:

-44 percent reduction in spinal fractures,

– 40 percent reduction in major fractures related to osteoporosis, and

– 28 percent lower risk of fragility fractures, which often result from minimal trauma such as a minor fall.

The simplicity and affordability of the treatment make it a viable option for millions of women. Zoledronate is a generic drug, and its infrequent administration – once every five years – reduces costs and potential side effects.

Risk of Fracture in Postmenopausal Women Postmenopausal women face a 50 percent risk of fracture in their lifetime due to age-related bone thinning and weakness. As estrogen levels drop during menopause, bone density decreases, making bones more likely to break. While zoledronate has long been used to treat osteoporosis, its effectiveness as a preventive measure in women with normal or near-normal bone density has not yet been fully explored.

study design

The trial involved more than 1,000 women with an average age of 56 years who were randomly assigned to receive two IV injections of zoledronate or placebo. The first dose was given at the beginning of the study, and the second was given five years later. Over the course of 10 years, researchers monitored the participants for fractures, etc. bone health,

Women who received zoledronate demonstrated significantly better results than women who took a placebo. In addition to reducing spine and major fractures, zoledronate reduced the risk of any fracture by 30 percent, emphasizing its potential as a preventive treatment for bone health in early postmenopause.

A new approach to fracture prevention

Dr. Boland and his team recommend that women concerned about fractures after menopause consider zoledronate infusions every five to ten years. This low-frequency regimen provides a practical solution to preventing bone loss without the burden of repeated treatments.

Dr. Roland Chapurlat, chief of rheumatology and orthopedics at Edouard Herriot Hospital in Lyon, France, echoed this sentiment in an editorial accompanying the study. She described the lower dose of zoledronate as “a real opportunity” for women to actively protect their bone health.

bone health support

While zoledronate provides a significant benefit, maintaining strong bones requires a holistic approach, including:

– Adequate calcium and vitamin D intake to maintain bone density,

– Regular weight-bearing exercises such as walking or resistance training,

– Avoid smoking and excessive alcohol consumption, which weaken bones, and

– Regular bone density checks to monitor bone health over time.

Get the latest news live on Times Now with breaking news and top headlines from around the world.